Clinical Trials
9 trialsNCT00820248 2023-08-22
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT03733210 2023-05-19
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Stanford University
Phase 1 Completed
NCT00446446 2022-10-05
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Amgen
Phase 2 Completed
NCT01264328 2019-04-16
VECTITAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Completed
NCT00500760 2018-10-17
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Amgen
Phase 2 Completed
NCT00798655 2017-10-03
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT00547157 2017-03-15
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Amgen
Phase 2 Completed
NCT01312493 2015-08-28
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01142414 2012-01-16
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Withdrawn